The DOI matches its Crossref record; 241 of the 243 references it cites were found in a registry or an index.
Progress in Antisense Technology
Abstract
Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Though fat accumulation, and specifically diacylglycerol accumulation, was equal in all groups, the PKCε antisense oligonucleotide improved hepatic insulin sensitivity and insulin signalling.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [107]
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,751
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Predicting DNA duplex stability from the base sequence
Breslauer, K. J., Frank, R., Blöcker, H., & Marky, L. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3746 · Cited by 1,837
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Functional genomic analysis of C. elegans chromosome I by systematic RNA interference
Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., & Ahringer, J. (2000) · Nature · doi:10.1038/35042517 · Cited by 1,761
SISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,352
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300
Morpholino Antisense Oligomers: Design, Preparation, and Properties
Summerton, J. E., & Weller, D. D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,137
Research works printed but not linked: 39
- Crouch RJ, 1985, Nucleases, 211
- Morvan F, 1991, Anticancer Drug Des., 6, 521
- Mirabelli CK, 1991, Anti-Cancer Drug Design, 6, 647
- 42. Cohen JS. 1993. Phosphorothioate oligodeoxynucleotides. See Ref.42a, pp.205–22
- Crooke ST, 1996, J. Pharmacol. Exp. Ther., 277, 923
- Joos RW, 1969, J. Pharmacol. Exp. Ther., 166, 113
- Crooke RM, 1995, J. Pharmacol. Exp. Ther., 275, 462
- Gao W-Y, 1992, Mol. Pharmacol., 41, 223
- Stein CA, 1991, J. Acquired Immune Deficiency Syndromes, 4, 686
- Cossum PA, 1993, J. Pharmacol. Exp. Ther., 267, 1181
- Crooke ST, 1993, Curr. Opin. Invest. Drugs, 2, 1045
- Sands H, 1995, Mol. Pharmacol., 47, 636
- Crooke RM, 1991, Anti-Cancer Drug Design, 6, 609
- 67. Crooke RM. 1993. in vitro and in vivo toxicology of first generation analogs. See Ref.42a, pp.471–92
- Bennett CF, 1992, Mol. Pharmacol., 41, 1023
- Iversen P, 1992, Anticancer Drug Des., 6, 531
- Cossum PA, 1994, J. Pharmacol. Exp. Ther., 269, 89
- 10.1038/clpt.1994.189 · DOI
- Butler M, 1997, Lab. Invest., 77, 379
- Sands H, 1994, Mol. Pharmacol., 45, 932
- Graham MJ, 1998, J. Pharmacol. Exp. Ther., 286, 447
- 95. Mirabelli CK, Crooke ST. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
- 103. Crooke ST, Mirabelli CK. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
- Zhang S-P, 1994, J. Pharmacol. Exp. Ther., 271, 1462
- Dean N, 1996, Cancer Res., 56, 3499
- Maksymowych W, 1999, Arthritis Rheumatol., 42, S170
- O'Dwyer PJ, 1999, Clin. Cancer Res., 5, 3977
- Henry SP, 1997, J. Pharmacol. Exp. Ther., 281, 810
- Cornish KG, 1993, Pharmacol.Comm., 3, 239
- Henry SP, 1997, Anti-Cancer Drug Des., 12, 395
- Wallace TL, 1996, J. Pharmacol. Exp. Ther., 278, 1306
- Henry S, 1994, Pharm. Res., 11, S-353/S1-S490
- Lemonidis-Farrar K, 2000, Toxicologist, 42, 120
- Yuen AR, 1999, Clin. Cancer Res., 5, 3357
- 164. Crooke ST. 2001. Basic principles. See Ref.46a, pp.1–28
- Zellweger T, 2001, J. Pharmacol. Exp. Ther., 298, 1
- Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 898
- Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 890
- Henry SP, 2000, J. Pharmacol. Exp. Ther., 292, 468
Cited by
Sorted by citations
Lipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 909
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
“Currently, over 20 antisense drugs are in various stages of clinical testing [12].”
BackgroundObesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
“ASOs are synthetic oligonucleotides modified with a 20-O-(2-methoxy) ethyl modification and phosphorothioate bond to enhance potency, stability, and cell permeability.(49) They are taken up preferentially in liver, adipose tissue, and the kidney, although not in other key tissues such as muscle, brain, or pancreatic b…”
BackgroundAlternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
“Oligonucleotide-mediated therapies Gene-specific therapy can be mediated by oligonucleotides or oligonucleotide-like compounds, some of which have been shown to have clinical effectiveness in other application”
Background
Metadata
- Authors
- Crooke, S. T.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Crooke, Stanley T.
- ORCID
- Crooke, Stanley T.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2004-02-01
- Volume
- 55
- Issue
- 1
- Pages
- 61-95
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2138668121
- Cited by
- 417
- References
- 243
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 24 · 2012: 32
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- antisense technology, oligonucleotide analogues, RNA hybridization, RNA degradation, RNA splicing, antisense drug development, pharmacokinetics, toxicity, target validation
- MeSH terms
- Animals, Humans, Oligonucleotides, Antisense, Biomedical Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
